Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
NCT ID: NCT00315640
Last Updated: 2012-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
70 participants
INTERVENTIONAL
2005-12-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anecortave Acetate 3 mg Depot
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate Sterile Suspension, 6 mg/mL
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate 15 mg Depot
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate Suspension Depot, 30 mg/mL
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate 30 mg Depot
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate Sterile Suspension, 60 mg/mL
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate Vehicle
Anecortave Acetate Vehicle
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anecortave Acetate Sterile Suspension, 6 mg/mL
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate Suspension Depot, 30 mg/mL
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate Sterile Suspension, 60 mg/mL
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate Vehicle
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or older
* IOP elevation caused by steroid usage
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Theresa Landry
Role: STUDY_DIRECTOR
Alcon Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jacksonville
Jacksonville, Florida, United States
Miami
Miami, Florida, United States
Detroit
Detroit, Michigan, United States
Fort Worth, Texas, United States
Houston
Houston, Texas, United States
San Paulo
São Paulo, , Brazil
Budapest
Budapest, , Hungary
Padova
Padua, , Italy
Amsterdam
Amsterdam, , Netherlands
Bayamon
Bayamón, , Puerto Rico
Barcelona
Barcelona, , Spain
Newcastle upon Tyne
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-001598-93
Identifier Type: -
Identifier Source: secondary_id
C-05-03
Identifier Type: -
Identifier Source: org_study_id